Summary
McKesson Corporation (MCK) filed an 8-K on January 30, 2012, to disclose the execution of a Purchase Agreement related to its Canadian operations. This agreement involves McKesson Canada Corporation, a wholly-owned subsidiary, in transactions with Katz Group Canada Inc., Drug Trading Company Limited, Katz Group Pharmacies Inc., and Daryl Katz. The filing primarily serves to announce this significant transaction through an attached press release. Investors should note that this 8-K is furnished for informational purposes under Regulation FD and is not deemed 'filed' in the traditional sense, meaning it doesn't automatically become incorporated into other SEC filings unless explicitly referenced. The core information revolves around the acquisition or divestiture agreement impacting McKesson's Canadian business, with further details expected in the accompanying press release.
Key Highlights
- 1McKesson Corporation announced the execution of a Purchase Agreement on January 30, 2012.
- 2The agreement involves McKesson Canada Corporation, a wholly-owned subsidiary.
- 3Key parties to the agreement include Katz Group Canada Inc., Drug Trading Company Limited, and Katz Group Pharmacies Inc., as well as Daryl Katz.
- 4The transaction is related to McKesson's Canadian operations.
- 5The 8-K filing includes a press release (Exhibit 99.1) as the primary disclosure vehicle for this event.
- 6The information furnished under Regulation FD is not deemed 'filed' for purposes of Section 18 of the Exchange Act unless expressly incorporated by reference.
- 7This filing signals a significant operational or structural change for McKesson in Canada.